CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
NCT05436093
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
18F-FDG
Sponsor
Peking University Cancer Hospital & Institute